Elliott H Sohn

Prof. Elliott H Sohn

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in The Lancet
Verified
Journal Article
Closed access
SRStephen R. Russell
Stephen R. Russell
JBJean Bennett
Jean Bennett
JWJennifer A Wellman
Jennifer A Wellman
DCDaniel C Chung
Daniel C Chung
ZYZi-Fan Yu
Zi-Fan Yu
AMAlbert M Maguire
Albert M Maguire

25 April 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ESElliott H Sohn
Elliott H Sohn
HDHille W. van Dijk
Hille W. van Dijk
CJChunhua Jiao
Chunhua Jiao
PKPauline H. B. Kok
Pauline H. B. Kok
WJWoojin Jeong
Woojin Jeong
MAMichael David Abràmoff
Michael David Abràmoff
Diabetic retinopathy (DR) has long been recognized as a microvasculopathy, but retinal diabetic neuropathy (RDN), characterized by inner retinal neurodegeneration, also occurs in people with diabetes mellitus (DM). We report that in 45 people with DM and no to minimal DR there was significant, progressive loss of the nerve fiber layer (NFL) (0.25 μm/y) and the ganglion cell (GC)/inner plexiform layer (0.29 μm/y) on optical coherence tomography analysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex. The NFL was significantly thinner (17.3 μm) in the eyes of six donors with DM than in the eyes of six similarly aged control donors (30.4 μm), although retinal capillary density did not differ in the two groups. We confirmed significant, progressive inner retinal thinning in streptozotocin-induced “type 1” and B6.BKS(D)-Leprdb/J “type 2” diabetic mouse models on OCT; immunohistochemistry in type 1 mice showed GC loss but no difference in pericyte density or acellular capillaries. The results suggest that RDN may precede the established clinical and morphometric vascular changes caused by DM and represent a paradigm shift in our understanding of ocular diabetic complications.

1 October 2013 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
DSDavid Sarraf
David Sarraf
EREhsan Rahimy
Ehsan Rahimy
AFAmani A. Fawzi
Amani A. Fawzi
ESElliott H Sohn
Elliott H Sohn
IBIrene Barbazetto
Irene Barbazetto
KFK. Bailey Freund
K. Bailey Freund
Research from JAMA Ophthalmology — Paracentral Acute Middle Maculopathy — A New Variant of Acute Macular Neuroretinopathy Associated With Retinal Capillary Ischemia

17 December 2018 in Nature Medicine
Verified
Journal Article
Closed access
Artur CideciyanArtur Cideciyan
Artur Cideciyan
SJSamuel Jacobson
Samuel Jacobson
ADArlene V. Drack
Arlene V. Drack
AHAllen C. Ho
Allen C. Ho
JCJason Charng
Jason Charng
SRStephen R. Russell
Stephen R. Russell

1 March 2015 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
SWS. Scott Whitmore
S. Scott Whitmore
ESElliott H Sohn
Elliott H Sohn
KCKathleen R. Chirco
Kathleen R. Chirco
ADArlene V. Drack
Arlene V. Drack
ESEdwin M. Stone
Edwin M. Stone
RMRobert Mullins
Robert Mullins

1 November 2014 in The American Journal of Pathology
Verified
Journal Article
Open access
RMRobert Mullins
Robert Mullins
DSDesi P. Schoo
Desi P. Schoo
ESElliott H Sohn
Elliott H Sohn
MFMiles J. Flamme-Wiese
Miles J. Flamme-Wiese
GWGrefachew Workamelahu
Grefachew Workamelahu
ESEdwin M. Stone
Edwin M. Stone
Age-related macular degeneration (AMD) is a common disease that can result in severe visual impairment. Abnormal regulation of the complement system has been implicated in its pathogenesis, and CFH polymorphisms contribute substantially to risk. How these polymorphisms exert their effects is poorly understood. We performed enzyme-linked immunosorbent assay (ELISA) analysis on young, aged, and AMD choroids to determine the abundance of the membrane attack complex (MAC) and performed immunofluorescence studies on eyes from 117 donors to evaluate the MAC in aging, early AMD, and advanced AMD. Morphometric studies were performed on eyes with high- or low-risk CFH genotypes. ELISA confirmed that MAC increases significantly with aging and with AMD. MAC was localized to Bruch's membrane and the choriocapillaris and was detectable at low levels as early as 5 years of age. Hard drusen were labeled with anti-MAC antibody, but large or confluent drusen and basal deposits were generally unlabeled. Labeling of retinal pigment epithelium was observed in some cases of advanced AMD, but not in early disease. Eyes homozygous for the high-risk CFH genotype had thinner choroids than low-risk homozygotes (P < 0.05). These findings suggest that increased complement activation in AMD and in high-risk genotypes can lead to loss of endothelial cells in early AMD. Treatments to protect the choriocapillaris in early AMD are needed.